PPT-Hepatitis C: A New Era In Treatment And Cure

Adam Deising DO LCDR MC USN Director of Hepatology Department of Gastroenterology Naval Medical Center San Diego Disclosures I have no financial disclosures I will be discussing some treatments that are not FDA approved and that are still in development. Dr. Joanna Eveland, MS, MD. Clinical Chief for Special Populations, MNHC. O. bjectives. Understand recommendations for age cohort and risk based screening for Hepatitis C. Review strategies for health promotion and optimizing treatment readiness for HCV infected homeless individuals. . -Stacey . Trooskin. MD, PhD, Drexel University & . HepCAP. . -Karen Arendt, RN, St. Joseph's Center for Liver & Hepatobiliary Disease. -Courtney Jones, Patient Advocate Foundation. www.nvhr.org/program. Diana L. . Sylvestre. , MD. University of CA, San Francisco. OASIS Clinic, Oakland, CA. Disclosure Information. What’s New In Hepatitis C. Diana . Sylvestre. , MD. I have the following financial relationships to disclose:. : . from. the . bench. to . public . health. perspectives. Pr Karine Lacombe, M.D., . PhD. Inserm UMR-S1136, IPLESP. Sorbonne Université, APHP. Paris - France. Chronic. Hep B, a . silent. and . New Therapies Can Cure 95% of Patients With HCV Infection. Treatment of HCV Infection. Cure, Risk Reduction, and Decreased All-Cause Mortality . Patient History. Clues to the Source and Timing of Acquisition of Infection. Genotype 1, never treated for HCV, no cirrhosis12 weeks (recommended): to (if HCV RNA is less than 6 million copies IU/mL, consider 8 weeks8 weeks: (if HCV RNA is less than 6 million copies IU/mL: 9 Rachel Stallings, MPH. March 4, 2020. Hepatitis . Hepatitis = inflammation of the liver. Can be self-limiting or progress to fibrosis (scarring), cirrhosis, or liver cancer. . Causes:. Most commonly caused by a virus, there are 5: A, B, C, D & E. Oluwatoyin ( . Toyin. ) Adeyemi, MD. Director, CORE Viral hepatitis Clinic. Senior director for HIV services, Cook County Health . Triple Threat 11: HIV, HCV & . Opiods. Dusable. Museum , June 25, 2019. October 1. st. , 2020. Participating in . GoToWebinar. Join on computer via this link to view presentation: . Audio – choose computer audio” . or. “phone call”. Phone Call: (415) 930-5229. Access Code: 613-500-454. �� &#x/MCI; 0 ;&#x/MCI; 0 ;TABLE OF CONTENTS &#x/MCI; 0 ;&#x/MCI; 0 ;1 &#x/MCI; 1 ;&#x/MCI; 1 ;Executive SummaryIntroductionStrategic Priority 1: Understanding Hepatitis Strategic Plan Working Group November 2019STRATEGIC PLAN FOR TRANSNIH RESEARCH TO CURE HEPATITIS B 1 Table of Contents Executive SummaryIntroductionStrategic Priority 1: Hepatitis B BiologyStrategi . TODAY. DIAGNOSIS. TREATMENT. SPECIAL SITUATIONS. COMPLICATIONS. VACCINATION. DIAGNOSIS. Time since infection. Relative amount. HBsAg. Anti-HBs. IgM anti-. HBc. Total anti-. HBc. Serological patterns of acute HBV infection. Navigating Hepatitis C: . What Patients Need to Know . avigating. Hepatitis C: . What Patients Need to Know. Need to Know. HCV Screening. Bruce Burkett. Executive Director. HepC Alliance. Persons who have ever injected illegal drugs, including those who injected only once many years ago. Jocelyn James, MD. Assistant Professor, Department of Medicine. University of Washington. . Adapted from slides developed in collaboration with Judith . Tsui. and the Washington State Department of Health.